First SARS-CoV-2 Omicron infection as an effective immune booster among mRNA vaccinated individuals: final results from the first phase of the PRIBIVAC randomised clinical trial

• Main Authors: Poh, Xuan Ying, Lee, I. Russel, Tan, Chee Wah, Chavatte, Jean-Marc, Fong, Siew Wai, Goh, Yun Shan, Rouers, Angeline, Wong, Nathan, Torres-Ruesta, Anthony, Mah, Shirley Y. Y., Yeoh, Aileen Y. Y., Gandhi, Mihir, Rahman, Nabilah, Chin, Yi Qing, Lim, J Jonathan, Yoong, Terence J. K., Rao, Suma, Chia, Po Ying, Ong, Sean W. X., Lee, Tau Hong, Sadarangani, Sapna P., Lin, Ray J. H., Lim, Daniel R. X., Chia, Wanni, Renia, Laurent, Ren, Ee Chee, Lin, Raymond T. P., Lye, David C., Wang, Lin-Fa, Ng, Lisa F. P., Young, Barnaby Edward
• Other Authors: Lee Kong Chian School of Medicine (LKCMedicine)
• Format: Article
• Language: English
• Published: 2024
• Subjects: Medicine, Health and Life Sciences; Cellular response; COVID-19 booster
• Online Access: https://hdl.handle.net/10356/181427
• Institution: Nanyang Technological University

Background: Understanding how SARS-CoV-2 breakthrough infections impacts the breadth of immune responses against existing and pre-emergent SARS-CoV-2 strains is needed to develop an evidence-based long-term immunisation strategy. Methods: We performed a randomised, controlled trial to assess the imm...